News | October 07, 2010

Blood Pressure Pills More Effective When Taken at Night

October 7, 2010 - Taking medication at night instead of in the morning significantly increases efficacy in keeping blood pressure within a healthy range, according to a new study in Chronobiology International. Additionally, taking medication at night offers extra protection against heart attacks, strokes and other types of cardiovascular diseases.

Two articles in Chronobiology International, the international journal on how biological rhythms affect the systems of living things, cover the results of the MAPEC study.

Over the five-year study, the group of patients who took at least one of their medications at night experienced just one-third of the number of cardiovascular disease (CVD) episodes experienced by the group of patients who took all their medications in the morning.

"This study proves that the time of day when patients take their high blood pressure medications can make a huge difference due to the effect of the body's circadian rhythms on the actions of medications and because of the importance of preserving the normal day-night pattern of blood pressure in hypertension," said professor Ramón C. Hermida, Ph.D., director of bioengineering and chronobiology labs at the University of Vigo in Spain and lead investigator of the MAPEC Study. "Conventional treatment typically advises taking blood pressure medications in the morning. The MAPEC study shows that conventional treatment is not the most effective way to help patients with high blood pressure.”

Based on around-the-clock ambulatory blood pressure monitoring, the study found that taking at least one blood pressure medication at bedtime was best at normalizing sleep-time blood pressure. This is known to be the most sensitive predictor of a patient's five-year risk of CVD mortality. In addition, the study shows that taking medication at night is the best way to control daytime BP levels.

"Historically, medical professionals have operated on the assumption that sleep-time blood pressure levels will drop by 10 to 20 percent from daytime levels. However, for many patients – called nondippers – this doesn't happen and sleep-time therefore becomes a high risk period," said Francesco Portaluppi, M.D., of the Hypertension Center at the University Hospital of Ferrara in Italy and lead author of the perspectives article on the MAPEC study. "This study was the first to conclusively find that the time of day when medications are ingested not only affects efficacy but also CVD risk and these findings must fundamentally change the way patients are treated worldwide."

"Our body clocks are extremely powerful biological tools and this study offers insight and hard facts on how we can harness that power to help millions of people stay healthier and safer by ensuring that their blood pressure medications are taken as effectively as possible," said Michael Smolensky, editor of Chronobiology International.

More than 70 million people in the United States have hypertension.

For more information: www.informahealthcare.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init